Recurring DLBCL after just 5 months is understandably stressful, but there are indeed other treatment options beyond CAR T-cell therapy and bone marrow transplant worth discussing with your oncologist.
Here are some second-line options that may be considered:
- Polatuzumab vedotin (Polivy) — with or without bendamustine Show Full Answer
Recurring DLBCL after just 5 months is understandably stressful, but there are indeed other treatment options beyond CAR T-cell therapy and bone marrow transplant worth discussing with your oncologist.
Here are some second-line options that may be considered:
- Polatuzumab vedotin (Polivy) — with or without bendamustine and/or rituximab
- Tafasitamab (Monjuvi) combined with lenalidomide (Revlimid)
- GemOx (gemcitabine + oxaliplatin), with or without rituximab
- Bispecific antibodies like epcoritamab (Epkinly) or glofitamab (Columvi), which help your immune system target cancer cells
- Clinical trials for newer immunotherapy approaches Since your DLBCL returned within a year of treatment, your oncologist will likely consider this high-risk relapse and tailor recommendations accordingly.
It's worth having an open conversation with your care team about eligibility for each option, as factors like overall health and how your cancer responded previously will guide the best path forward.
October 10
Join
Your Privacy Choices
